MRK Earnings & Financial Statements
Merck & Co., Inc.
$147.37
+$5.39(+3.80%)
67
Overall
80
Value
60
Tech
63
Quality
Market Cap
$350.29B
Volume
9.79M
52W Range
$82.01 - $156.92
Target Price
$158.74
MRK earnings and financial statements: Merck & Co., Inc.'s income statement, balance sheet and cash flow statement, annual and quarterly.
MRK Annual Financial Statements
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | $65.01B | $64.17B | $60.12B | $59.28B | $48.70B |
| Cost of revenue | $16.38B | $15.19B | $16.13B | $17.41B | $13.63B |
| Operating income | $22.11B | $20.22B | $2.95B | $18.28B | $13.20B |
| EBITDA | $28.22B | $25.70B | $6.88B | $21.29B | $17.90B |
| Net income | $18.25B | $17.12B | $365.00M | $14.52B | $13.05B |
| EPS (diluted) | $7.28 | $6.74 | $0.14 | $5.71 | $5.14 |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total assets | $136.87B | $117.11B | $106.67B | $109.16B | $105.69B |
| Total liabilities | $84.20B | $70.73B | $69.04B | $63.10B | $67.44B |
| Shareholders’ equity | $52.61B | $46.31B | $37.58B | $45.99B | $38.18B |
| Cash and equivalents | $14.56B | $13.24B | $6.84B | $12.69B | $8.10B |
| Long-term debt | $46.75B | $34.46B | $33.68B | $28.75B | $30.69B |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating cash flow | $16.47B | $21.47B | $13.01B | $19.09B | $14.11B |
| Capital expenditure | -$4.11B | -$3.37B | -$3.86B | -$4.39B | -$4.45B |
| Free cash flow | $12.36B | $18.10B | $9.14B | $14.71B | $9.66B |
| Dividends paid | $8.18B | $7.84B | $7.45B | $7.01B | $6.61B |
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | MRK | $147.37 | +3.8% | 9.79M |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |